BostonGene to Participate in The Festival of Genomics & Biodata 2025
BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced its participation in The Festival of Genomics & Biodata 2025, held January 29 – 30, at ExCel in London, UK. Celebrating its 10th anniversary, the Festival is the UK’s largest life sciences event, offering an expanded lineup of topics including biodata, diagnostics, cancer research, AI and multiomics.
Joe Lennerz, MD, PhD, BostonGene’s Chief Scientific Officer, will deliver a presentation, "Genomics at Machine Speed" highlighting the transformative role of machine-driven advancements in genomics and high-complexity testing for healthcare. His talk will cover key themes such as AI-driven genomic analysis, integrated diagnostics, scaling precision medicine, operationalizing genomics and the future of multiomics and automation in precision oncology."
Date & time: Thursday, January 30 | 11:50 AM – 12:20 PM
Location: Live Lounge
BostonGene will also showcase its innovative solutions at booth 89A.
To schedule a meeting during the event, please contact Erin Keleher at [email protected]. For more details about the event, visit The Festival of Genomics & Biodata website.
About BostonGene Corporation
BostonGene powers an AI model of tumor and immune biology to deliver disease-level insights and enable precision decision-making across oncology and immune-mediated diseases, spanning drug development and clinical care. By integrating multimodal data, including genomic, transcriptomic, immune, and clinical signals, BostonGene generates biologically grounded intelligence to optimize patient selection, trial design, and therapeutic strategy. This creates a scalable AI decision layer that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical organizations and academic institutions to accelerate the delivery of precision therapies while continuously expanding its capabilities across new diseases and complex biological systems. For more information, visit www.BostonGene.com.
Latest news
